Company: LENZ
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001628280-25-016822
Chunk: 35

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: S-3
Chunk 35
---
 for the year ended December 31, 2024, filed with the SEC on March 19, 2025 ; and

• the description of our Common Stock contained in the Annual Report on Form 10-K filed on March 19, 2025 .

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address and telephone number:

<div align='center'>LENZ Therapeutics, Inc.

201 Lomas Santa Fe Dr., Suite 300

Solana Beach, California 92075

Attn: Investor Relations

(858) 925-7000

26</div>

The information in this prospectus supplement is not complete and may be changed. The securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

#### SUBJECT TO COMPLETION, DATED April 4, 2025

#### PROSPECTUS SUPPLEMENT

#### Up to $150,000,000

#### Common Stock
We have entered into a sales agreement (the “sales agreement”) with TD Securities (USA) LLC (“TD Cowen”), dated April 4, 2025, relating to shares of our common stock, par value $0.00001 per share (“common stock”), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time through TD Cowen acting as our agent or principal.

Our common stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “LENZ.” On April 3, 2025, the last reported sale price of our common stock on Nasdaq was $23.00 per share.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in negotiated transactions, including block trades, in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or by any other method permitted by law. TD Cowen is not required to sell any specific number of dollar amount of securities, but